Adma Biologics traded at $16.43 this Friday February 6th, increasing $0.49 or 3.07 percent since the previous trading session. Looking back, over the last four weeks, Adma Biologics gained 12.70 percent. Over the last 12 months, its price fell by 1.68 percent. Looking ahead, we forecast Adma Biologics to be priced at 16.77 by the end of this quarter and at 15.27 in one year, according to Trading Economics global macro models projections and analysts expectations.
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.